emd 53998 has been researched along with Heart Failure in 12 studies
*Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fuhrer, W; Herold, P; Herzig, JW; Leutert, T; Meier, M; Rihs, G; Schenker, K; Stutz, S; Wenk, P; Zbinden, P | 1 |
| Irving, T; Jani, V; Ma, W; Qian, W; Yuan, S | 1 |
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
| Endoh, M | 1 |
| Borbély, A; Edes, I; Papp, Z; Stienen, GJ; Van Der Velden, J | 1 |
| Brixius, K; Schwinger, RH | 1 |
| Gwathmey, JK; Hajjar, RJ; Helm, P; Schmidt, U | 1 |
| Holubarsch, C | 1 |
| Allen, DG; Lee, JA | 1 |
| Arimura, K; Egashira, K; Ide, T; Kinugawa, S; Nakamura, R; Takeshita, A; Tsutsui, H | 1 |
| Atsumi, H; Endoh, M; Nakada, S; Sakurai, K; Sugawara, H; Tomoike, H | 1 |
| Egashira, K; Makino, N; Satoh, S; Suematsu, N; Takeshita, A; Tsutsui, H; Ueda, Y | 1 |
3 review(s) available for emd 53998 and Heart Failure
| Article | Year |
|---|---|
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C | 2008 |
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
Topics: Actin Cytoskeleton; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; Myocardium; Oxygen Consumption; Pyridazines; Quinolines; Simendan; Thiadiazines | 2005 |
Calcium sensitisers: mechanisms of action and potential usefulness as inotropes.
Topics: Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Quinolines; Thiadiazines | 1997 |
9 other study(ies) available for emd 53998 and Heart Failure
| Article | Year |
|---|---|
5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4-dione (BA 41899): representative of a novel class of purely calcium-sensitizing agents.
Topics: Animals; Azocines; Calcium; Cardiotonic Agents; Electric Stimulation; Guinea Pigs; Heart Atria; Heart Failure; Imidazoles; In Vitro Techniques; Isometric Contraction; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Sensitivity and Specificity; Stereoisomerism; Swine | 1995 |
EMD-57033 Augments the Contractility in Porcine Myocardium by Promoting the Activation of Myosin in Thick Filaments.
Topics: Animals; Heart Failure; Myocardium; Myocytes, Cardiac; Myosins; Swine; Troponin | 2022 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.
Topics: Acetamides; Adult; Aged; Calcium; Cell Membrane Permeability; Female; Heart Failure; Humans; In Vitro Techniques; Male; Middle Aged; Myocardium; Myocytes, Cardiac; Pyridazines; Quinolines; Thiadiazines; Tissue Donors | 2004 |
Ca++ sensitizers impair cardiac relaxation in failing human myocardium.
Topics: Adult; Calcium; Cardiotonic Agents; Diastole; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Organic Chemicals; Quinolines; Thiadiazines | 1997 |
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failure; Humans; Imidazoles; In Vitro Techniques; Isoproterenol; Myocardial Contraction; Myocardium; Papillary Muscles; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinolines; Thiadiazines | 1997 |
Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes.
Topics: Actin Cytoskeleton; Analysis of Variance; Animals; Calcium; Cardiac Pacing, Artificial; Cell Size; Cholinesterase Inhibitors; Cholinesterase Reactivators; Diacetyl; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Growth Hormone; Heart Failure; Homeostasis; In Vitro Techniques; Insulin-Like Growth Factor I; Myocardial Contraction; Myocardium; Quinolines; Stimulation, Chemical; Thiadiazines | 1999 |
Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Drug Evaluation, Preclinical; Electrocardiography; Heart Failure; Hemodynamics; Isoproterenol; Male; Myocardial Contraction; Myofibrils; Phosphodiesterase Inhibitors; Quinolines; Rabbits; Thiadiazines | 2000 |
Post-beta-receptor impairment in the regulation of myofibrillar Ca2+ sensitivity in tachypacing-induced canine failing heart.
Topics: Animals; Blotting, Western; Calcium; Cell Size; Cyclic AMP; Dogs; Electrophoresis, Polyacrylamide Gel; Heart Failure; Myocardial Contraction; Myocardium; Myofibrils; Pacemaker, Artificial; Phosphodiesterase Inhibitors; Phosphorylation; Quinolines; Receptors, Adrenergic, beta; Signal Transduction; Thiadiazines; Troponin I; Ventricular Function, Left | 2002 |